Endocrinology, Vol 126, 1756-1763, Copyright © 1990 by Endocrine Society

ARTICLES

Presence of immunoreactive vasoactive intestinal polypeptide in anterior pituitary of normal male and long term estrogen-treated female rats: a light microscopic immunohistochemical study

K Koves, PE Gottschall, T Gorcs, JG Scammell and A Arimura
U.S. Japan Biomedical Research Laboratories, Tulane University, Belle Chasse, Louisiana 70037.

The presence and synthesis of vasoactive intestinal polypeptide (VIP) has been demonstrated in the rat anterior pituitary. It was recently confirmed that immunoreactive VIP is present in the anterior pituitary, and in a thyroid-deficient state, VIP could be detected by light microscopic immunohistochemistry. It has also been suggested that VIP plays a stimulatory role in PRL secretion. To gain more detailed information on the localization of VIP and the conditions that alter the synthesis of VIP, we examined VIP immunoreactivity using immunohistochemistry in pituitaries of normal male and cycling female rats and in those states in which PRL secretion was enhanced (pregnancy, lactation, long term estrogen treatment, and pituitary implanted under kidney capsule of normal or estrogen-treated female rats). In situ, implanted and cultured pituitary cells were stained for VIP immunoreactivity using the peroxidase-antiperoxidase method. VIP immunoreactivity was observed in about 45% of the male rats, in all estrogen-treated female rats, in the implanted pituitaries under the kidney capsule (three of five from estrogen-treated and one of five from intact females, respectively), and in the pituitary cell cultures derived from estrogen-treated rats. Using a double labeling procedure we have also observed PRL immunoreactivity in a small population of the VIP-positive cells. These results suggest a positive regulatory role of estrogen in expression of the VIP gene. The physiological and pathophysiological significance of VIP in PRL secretion, however, remains to be clarified.

This article has been cited by other articles:

				M. Barberi, B. Muciaccia, M. B. Morelli, M. Stefanini, S. Cecconi, and R. Canipari Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary Reproduction, August 1, 2007; 134(2): 281 - 292. [Abstract] [Full Text] [PDF]

				A. Lacombe, V. Lelievre, C. E Roselli, J.-M. Muller, J. A Waschek, and E. Vilain Lack of vasoactive intestinal peptide reduces testosterone levels and reproductive aging in mouse testis J. Endocrinol., July 1, 2007; 194(1): 153 - 160. [Abstract] [Full Text] [PDF]

				O. Gomez and J. A. Balsa Autocrine/Paracrine Action of Pituitary Vasoactive Intestinal Peptide on Lactotroph Hyperplasia Induced by Estrogen Endocrinology, October 1, 2003; 144(10): 4403 - 4409. [Abstract] [Full Text] [PDF]

				M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]

				J. J. Evans Modulation of Gonadotropin Levels by Peptides Acting at the Anterior Pituitary Gland Endocr. Rev., February 1, 1999; 20(1): 46 - 67. [Abstract] [Full Text]

				F. El-Gehani, M. Tena-Sempere, and I. Huhtaniemi Vasoactive Intestinal Peptide Is an Important Endocrine Regulatory Factor of Fetal Rat Testicular Steroidogenesis Endocrinology, April 1, 1998; 139(4): 1474 - 1480. [Abstract] [Full Text] [PDF]